Retinalyze, LLC Signs Licensing Agreement For Vision Plan Reimbursement

Retinalize, LLC is pleased to announce that it has signed an agreement to begin using the Retinalytics SVM TM analysis technology for Vision Care Direct and associated vision health and wellness plans. Retinalize, LLC is a 50%/50% joint venture between Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, and Doctors Optimal Formula LLC , a physician exclusive anti-aging, health and wellness company.

Retinalytics SVM TM is to be used for Vision Care Direct’s Vision Plans and corresponding Independent Physician Associations (IPA) systems which currently have well over 3 million patient lives covered. In addition to the current Retinalytics SVM TM module for macular degeneration, Retinalize, LLC is currently completing a module for Alzheimer’s detection and beginning development on a module for Diabetic Retinopathy. Vision Care Direct intends to utilize these multiple modules to create wellness plans using Retinalytics SVM TM to assist physicians as their primary screening tool.

Reid Nelson, President, Vision Care Direct, states, “Vision Care Direct (VCD) and the doctors of the Independent Physician Associations (IPA) are excited about reaching an agreement with Retinalize, LLC to utilize their Retinalytics SVM TM analysis technology. VCD is pleased to be adding Retinalytics SVM TM technology to its product offerings and rolling out a new product that embeds Retinalytics SVM TM as a covered benefit. This SVM technology and the new Retinalytics SVM TM products come at a time when health plans, governments and employers are discovering that comprehensive eye exams can saves lives and lower health care costs. The SVM technology could allow comprehensive eye exams to become a fundamental building block of any health care regimen.”

“The incorporation of Retinalytics SVM TM into Vision Care Direct’s Vision Plan, will give us national exposure to patients and providers alike,” said Howard Loff, M.D., CEO of Retinalyze, LLC. “With Retinalytics SVM TM now becoming a reimbursed covered benefit, we expect near 100% utilization by these newly covered patients.”

Ronald Fiegel, OD, President of the Kansas IPA, Vision Care Plus, Inc., notes, “In addition to our Vision Care Direct Members, Vision Care Plus is actively exploring opportunities that will allow our providers to utilize Retinalytics SVM TM technology in caring for the approximately 500,000 lives we have under primary eye care contracts throughout Kansas. We also see this as a valuable contributor to the enhanced well care and cost savings needed to make Accountable Care Organization's and Medical Homes a reality for the millions of patients with life altering diseases such Diabetes and Alzheimer's.”

Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, added, “We are very excited to see HDC's SVM technology being incorporated as a reimbursed test procedure within these vision plans. We are proud of the fact that Retinalytics SVM TM could set a new standard of care by assisting physicians in the eye care industry.”

Eye Doctors and patients interested in learning more about Vision Care Direct, please visit

About Doctors Optimal Formula LLC

Having been founded by medical doctors, Doctors Optimal Formula prides itself on providing the best, scientifically formulated nutritional supplements and anti-aging skin care available today! Focusing on maintaining and improving the health and well-being of our customers, Doctors Optimal Formula has become vertically integrated to encompass all aspects of healthcare, such as Vision Care Plans, Prescription Pharmacy Plans and a physician provider network of over 10,000 physicians. For more information, visit

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Copyright Business Wire 2010